CRISPR reprioritizes CAR-T pipeline with cuts, expands into autoimmune disease as US decision for exa-cel looms
CRISPR Therapeutics is making several changes to its allogeneic CAR-T cell therapy pipeline, including program cuts and moving into a new indication as it awaits an FDA decision on its Vertex-partnered CRISPR-edited therapy exa-cel.
The Swiss company is axing two of its original CAR-T programs — CTX110 and CTX130 — to prioritize two next-generation candidates with the potential for improved clinical profiles according to preliminary data from early trials. CRISPR said it will transition patients treated with CTX110 and CTX130 to long-term follow-up programs where relevant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.